68Ga-Pentixafor PET/CT在新诊断多发性骨髓瘤评估中与18F-FDG PET/CT的比较
68Ga-Pentixafor PET/CT阳性率显著高于18F-FDG PET/CT(93.3% vs. 53.3%,p=0.0005),且其骨髓摄取定量值与终末器官损害、分期及肿瘤负荷相关实验室指标正相关。
要点
- 68Ga-Pentixafor PET/CT在新诊断MM中阳性率高于18F-FDG PET/CT。
- 68Ga-Pentixafor骨髓摄取值与终末器官损害、分期及肿瘤负荷指标正相关。
- 18F-FDG PET/CT仅总骨髓SUVmean与血清游离轻链及24小时尿轻链正相关。
核心结论
- 68Ga-Pentixafor PET/CT在新诊断多发性骨髓瘤评估中有应用前景。
研究设计与样本
- 所有患者入组后1周内行68Ga-Pentixafor与18F-FDG PET/CT检查。
- 阳性PET/CT定义为骨髓内存在局灶性PET阳性病灶或弥漫性骨髓模式(摄取>肝脏)。
- 通过在PET/CT上勾画全骨髓感兴趣体积获得骨髓摄取定量值。
主要发现
- 68Ga-Pentixafor PET/CT阳性率高于18F-FDG PET/CT(93.3% vs. 53.3%,p=0.0005)。
- 68Ga-Pentixafor骨髓摄取值(TBmUCXCR4、SUVmax、SUVmean)与终末器官损害、分期及肿瘤负荷相关实验室指标(血清β2-微球蛋白、血清游离轻链、24小时尿轻链)正相关(p<0.05)。
- 18F-FDG PET/CT中仅总骨髓SUVmean与血清游离轻链及24小时尿轻链正相关(p<0.05)。
关键数值与推荐
- 阳性PET/CT判定标准:骨髓内局灶性PET阳性病灶或弥漫性骨髓模式(摄取>肝脏)。
临床怎么用
- 在新诊断多发性骨髓瘤评估中,68Ga-Pentixafor PET/CT可能较18F-FDG PET/CT提供更高的阳性检出。
- 68Ga-Pentixafor骨髓摄取定量值或有助于反映肿瘤负荷与分期相关特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: 18F-FDG PET/CT has some limitations in the evaluation of multiple myeloma (MM). Since chemokine receptor-4 is overexpressed in MM, we perform a prospective cohort study to compare the performance of 68Ga-Pentixafor and 18F-FDG PET/CT in newly diagnosed MM. METHODS: Thirty patients with newly diagnosed MM were recruited. All patients underwent 68Ga-Pentixafor and18F-FDG PET/CT within 1 week after enrollment. A positive PET/CT was defined as the presence of focal PET-positive lesions in bone marrow or diffuse bone marrow patterns (uptake > liver). Bone marrow uptake values in 68Ga-Pentixafor and18F-FDG PET/CT (total bone marrow glycolysis [TBmGFDG], total bone marrow uptake with 68Ga-Pentixafor [TBmUCXCR4], total bone marrow volume [TBmV], SUVmean, and SUVmax) were obtained by drawing total bone marrow volume of interest on PET/CT. The positive rates of the PET/CT scans were statistically compared, and the correlation between quantitative bone marrow uptake values and clinical characteristics, laboratory findings, and staging was analyzed. RESULTS: 68Ga-Pentixafor PET/CT had a higher positive rate than 18F-FDG PET/CT in recruited patients (93.3 vs. 53.3%, p = 0.0005). In quantitative analysis, bone marrow uptake values in 68Ga-Pentixafor (TBmUCXCR4, SUVmax, and SUVmean) were positively correlated with end organ damage, staging, and laboratory biomarkers related to tumor burden including serum β2-microglobulin, serum free light chain, and 24-h urine light chain (p < 0.05). In 18F-FDG PET/CT, only the SUVmean of total bone marrow was positively correlated with serum free light chain and 24-h urine light chain (p < 0.05). CONCLUSIONS: 68Ga-Pentixafor PET/CT is promising in assessment of newly diagnosed MM. TRIAL REGISTRATION NUMBER: NCT03436342.
引用
- Pan Q, Cao X, Luo Y, et al. Chemokine receptor-4 targeted PET/CT with 68Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2019. PMID: 31776631. doi:10.1007/s00259-019-04605-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。